FDA Approves Direct Biologics to Proceed with a Landmark Phase III Acute Respiratory Distress Syndrome (ARDS) Trial

Direct Biologics announced that the FDA has approved the company to proceed with its Phase III clinical trial using its investigational EV drug, ExoFlo, to treat ARDS due to COVID-19.